Sign in Subscribe
Nervous system diseases

Klotho Neurosciences Expands into New Technologies for Improved Muscle Strength, Bone Health, and Longevity Indicators

Strategic Insights

— 1 min read

Klotho Neurosciences, Inc., a biogenetics company, is evaluating the acquisition of complementary technologies aimed at supporting healthy brain function, organ health, and longevity. The company is building upon its core programs targeting brain aging and neurodegenerative diseases, such as ALS, Alzheimer's, and Parkinson's, by expanding into adjacent technologies that complement its proprietary anti-aging Klotho platform. This includes exploring other treatments that could support healthy aging and extend human longevity.

Key Takeaways:

  • Klotho Neurosciences is pursuing the acquisition of complementary technologies to support healthy brain function, organ health, and longevity.
  • The company's proprietary anti-aging Klotho platform is focused on slowing biological aging and reducing the burden of age-related diseases.
  • The human Klotho gene is strongly linked to aging and longevity, with levels declining with age contributing to age-related disorders.
  • Silencing of the Klotho gene has been shown to accelerate multi-organ deterioration.
  • The company is evaluating genes and proteins such as alpha-Klotho, beta-Klotho, FOXO3, anti-myostatin, and their isoforms.
  • Dr. Joseph Sinkule, CEO, stated that the company's mission is to identify and develop complementary assets to delay age-related outcomes through targeted research and intervention.
  • Jeffrey LeBlanc, CFO, added that the company is assembling a team of scientists, clinicians, and business leaders focused on identifying key longevity indicators.

Statistics:

  • The human Klotho gene is linked to aging and longevity, with levels declining with age contributing to age-related disorders.
  • 75% of age-related diseases are linked to the decline of the Klotho gene.
  • Silencing of the Klotho gene accelerates multi-organ deterioration.
  • December 2023: KLTO-101 and KLTO-202 commence manufacturing and clinical development.
  • 2025: The company's current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays.

Sources:

  • Klotho Neurosciences, Inc. press release, July 24, 2025
  • Company website:

Read more